Laxmi Rani

Dr. Laxmi Rani


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Mithun RudrapalMithun Rudrapal
Mithun Rudrapal
AMAshwini Kumar Mishra
Ashwini Kumar Mishra
LRLaxmi Rani
Laxmi Rani
KSKhomendra K. Sarwa
Khomendra K. Sarwa
JZJames H. Zothantluanga
James H. Zothantluanga
PSPravat K. Sahoo
Pravat K. Sahoo
Advancement in nanotechnology has unleashed the therapeutic potentials of dietary polyphenols by enhancing bioavailability, improving biological half-life, and allowing site-specific drug delivery. In this review, through citation of relevant literature reports, we discuss the application of nano-pharmaceutical formulations, such as solid lipid nanoparticles, nano-emulsions, nano-crystals, nano-polymersomes, liposomes, ethosomes, phytosomes, and invasomes for dietary polyphenols. Following this, we highlight important studies concerning different combinations of nano formulations with dietary polyphenols (also known as nanophytopolyphenols). We also provide nano-formulation paradigms for enhancing the physicochemical properties of dietary polyphenols. Finally, we highlight the latest patents that were granted on nano-formulations of dietary polyphenols. Based on our review, we observe that nanosized delivery of herbal constituents, spices, and dietary supplements have the ability to improve biological processes and address issues connected with herbal treatments.

27 May 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
AMAshwini Kumar Mishra
Ashwini Kumar Mishra
SNS.L. Neha
S.L. Neha
LRLaxmi Rani
Laxmi Rani
Ankit JainAnkit Jain
Ankit Jain
HDHitesh Kumar Dewangan
Hitesh Kumar Dewangan
PSPravat Kumar Sahoo
Pravat Kumar Sahoo

11 September 2022 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
SPShweta Paroha
Shweta Paroha
JVJuhi Verma
Juhi Verma
Arvind Singh ChandelArvind Singh Chandel
Arvind Singh Chandel
SKShalini Kumari
Shalini Kumari
LRLaxmi Rani
Laxmi Rani
RDRikeshwer Prasad Dewangan
Rikeshwer Prasad Dewangan

1 February 2025 in Recent Patents on Nanotechnology
Verified
Journal Article
Closed access
PDF file
PMPooja Mathur
Pooja Mathur
Ravinder VermaRavinder Verma
Ravinder Verma
LRLaxmi Rani
Laxmi Rani
SKSweta Kamboj
Sweta Kamboj
RKRohit Kamboj
Rohit Kamboj
SBShailendra Bahtt
Shailendra Bahtt
Poloxamers, commonly known as Pluronics, are a special family of synthetic tri-block copolymers with a core structure made of hydrophobic poly (propylene oxide) chains sandwiched by two hydrophilic poly (ethylene oxide) chains. It is possible to modify the mechanical, bioactive, and microstructural characteristics of Pluronics to simulate the behavior of different types of tissues. Additionally, they are auspicious drug carriers with the capacity to increase therapeutic agent availability and to design nano-drug formulations for various ailments. The nanoformulation composed of Pluronics is more susceptible to cancer cells due to their amphiphilic nature and feature of selfassembling into micelles. Today's expanding poloxamer research is creating new hopes that increase the possibility of new remedies for a brand-new nanomedicine age treatment. This article provides a concise overview of the classification, grading, and attributes of drug delivery systems (DDSs) as well as the potential for Pluronics to create micro and nanocarriers. We subsequently discuss its utility in drug delivery for cancer, gene therapy, anti-infective therapy, antioxidants, anti-diabetic drugs, anti-HIV, Alzheimer's disease, and antimicrobial drugs. This review also highlighted several patented formulations that contain various grades of Pluronics in one or more different ways. The recent findings in fundamental research in the field properly demonstrate the strong interest in these novel pharmaceutical strategies.

1 June 2025 in Recent Advances in Inflammation & Allergy Drug Discovery
Verified
Journal Article
Closed access
PDF file
MMMohd Monis
Mohd Monis
PMPooja Mathur
Pooja Mathur
R.Ritu .
Ritu .
AMAshwini Kumar Mishra
Ashwini Kumar Mishra
LRLaxmi Rani
Laxmi Rani
Psoriasis, a chronic inflammatory skin disorder affecting approximately 2% of the global population, is characterized by a complex interplay of immunological dysregulation, genetic predisposition, and environmental factors. This review explores the dynamic mechanisms underlying psoriasis, highlighting the role of T lymphocytes in targeting healthy skin cells, leading to inflammation and the formation of characteristic white scaly patches on various body parts. Over the past 15 years, significant strides in unraveling the origins of psoriasis have paved the way for the development of precise and highly effective treatments. Key insights into the pathogenesis, particularly the dominance of interleukin-17 (IL-17) and interleukin-23 (IL-23), have shaped therapeutic strategies to mitigate chronic inflammatory disorders. Notably, various therapies employing different mechanisms of action, including interleukin blockers and tumor necrosis factor-alpha (TNF- α) inhibitors, have emerged as valuable options for psoriasis management. This review provides a comprehensive overview of the current understanding of psoriasis pathophysiology and highlights advanced therapeutic approaches that are widely accessible. The focus extends to emerging targeted drugs, such as netakimab, which functions as an interleukin-17 blocker, currently undergoing clinical trials for psoriasis treatment. By synthesizing the latest research findings, this article aims to contribute to the knowledge base surrounding psoriasis, offering clinicians and researchers valuable insights into the evolving landscape of psoriasis treatment modalities.

11 July 2026 in DARU Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
ASAakash Sharma
Aakash Sharma
AMAshwini Kumar Mishra
Ashwini Kumar Mishra
PMPooja Mathur
Pooja Mathur
Rahul Pratap SinghRahul Pratap Singh
Rahul Pratap Singh
LRLaxmi Rani
Laxmi Rani